Latest Infliximab Stories

SPRING HOUSE, Pa., Oct. 17, 2012 /PRNewswire/ -- Findings from a Janssen Research & Development, LLC (Janssen)-sponsored Phase 2b trial evaluating the efficacy and safety of STELARA(®) (ustekinumab) in the treatment of moderate to severe Crohn's disease appeared today in The New England Journal of Medicine. The results showed that among patients who had previously failed or were intolerant to at least one tumor necrosis factor (TNF) antagonist, a significantly greater...

ABBOTT PARK, Ill., Sept. 28, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved HUMIRA(®) (adalimumab) for inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis (UC) when certain other medicines have not worked well enough. Combined with its approval to treat moderate to severe Crohn's disease, HUMIRA is now approved for the treatment of two primary...

Researchers at Emory University have found that a medication that inhibits inflammation may offer new hope for people with difficult-to-treat depression. The study was published Sept. 3 in the online version of Archives of General Psychiatry. "Inflammation is the body's natural response to infection or wounding, says Andrew H. Miller, MD, senior author for the study and professor of Psychiatry and Behavioral Sciences at Emory University School of Medicine. "However when prolonged or...

Lee Rannals for redOrbit.com – Your Universe Online People suffering from ulcerative colitis may be getting some new relief due to a decision by the Food and Drug Administration (FDA) to expand the use of a new drug to help alleviate symptoms. An FDA panel voted 15 to 2 that the benefits of Humira outweighed the risks it causes when treating the condition. Humira is already approved to be used for six other conditions, and is most popular for its use to help in rheumatoid arthritis...

Oral drug shows clinical response and remission in some patients An investigational drug currently under FDA review for the treatment of rheumatoid arthritis has now shown positive results in patients with moderate-to-severe ulcerative colitis, according to researchers at the University of California San Diego, School of Medicine. The study will appear in the August 16, 2012 issue of the New England Journal of Medicine (NEJM). Results from the phase 2 clinical trial showed the drug...

Study compares overall mortality in TNF inhibitors: Humira, Enbrel, and Remicade New research confirms no significant difference in the rates of death among patients with rheumatoid arthritis (RA) who were exposed to one of several TNF inhibitors used to treat RA, adalimumab (Humira), etanercept (Enbrel), and infliximab (Remicade). This population-based study of RA patients in Sweden—the first to compare mortality rates among patients treated with individual TNF inhibitors—is now...

SAN DIEGO, July 31, 2012 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced today the market launch of its proprietary new generation monitoring test, PROMETHEUS Anser IFX. This test measures drug (infliximab) and drug antibody levels in one sample among inflammatory bowel disease (IBD) patients using infliximab - helping physicians identify potential causes for loss of treatment response and helping to guide patient...

NEW YORK, July 25, 2012 /PRNewswire/ -- Pharmspective, LLC, the specialty therapeutics market research firm, announced today the release of its two newest syndicated market research reports, Rheumatoid Arthritis Pipeline Perspectives - http://bit.ly/MjeXFo and Psoriasis Pipeline Perspectives - http://bit.ly/PKpqK0 These new Pharmspective reports coincide with a number of key milestones in Rheumatoid Arthritis (RA) & Psoriasis product development: Tofacitinib 2nd line...

CHAPEL HILL, N.C., July 6, 2012 /PRNewswire/ -- Chronic conditions such as rheumatoid arthritis and osteoporosis are complex and expensive to treat. But tech-savvy patients take solace in trusted chronic care product websites that help them understand their condition and treatment options better. The need to engage patients in critical information exchange has made it vital for chronic care product websites to effectively present information. For pharmaceutical companies -...

The latest regional Outpatient Infusion Center officially opened this week at Stafford Hospital, Mary Washington Healthcare. Stafford, VA (PRWEB) June 22, 2012 The latest regional Outpatient Infusion Center officially opened this week at Stafford Hospital, Mary Washington Healthcare. Using the latest technology, the Outpatient Infusion Center will provide care for patients who need infusion therapy or injection therapy. A dedicated nurse, specially trained in chemotherapy is always...